RxDoctor Payments Data

Megan Boyce

Nurse Practitioner · Sewell, NJNPI 1811442478

Payments from drug & device makers

$1,026in general payments, 2019–2025

Across 39 payments — averaging $26.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$235
  • AbbVie$225
  • LEO Pharma Inc.$169
  • Regeneron Healthcare Solutions, Inc.$109
  • Incyte Corporation$76
  • Amgen$75
  • plus $137 from 6 others

What the payments were for

  • Food & beverage$85183%
  • Education$17617%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,026 in reported general payments places this provider in the 80th percentile of 2,138 nurse practitioner providers in New Jersey.

See all nurse practitioner providers in New Jersey

Medicare billing

Part B allowed, 2024
$34,573
Medicare patients
181
Services billed
495

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban36$47,516
OzempicSemaglutide37$46,328
JardianceEmpagliflozin32$38,259
FarxigaDapagliflozin Propanediol22$25,939
InvokanaCanagliflozin16$19,485
MounjaroTirzepatide16$18,576
MyrbetriqMirabegron14$17,670
JanuviaSitagliptin Phosphate11$16,196
Breo ElliptaFluticasone/Vilanterol16$9,728
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$7,313
VascepaIcosapent Ethyl11$3,928
Rosuvastatin Calcium228$3,925
Atorvastatin Calcium259$3,611
Advair DiskusFluticasone Propion/Salmeterol14$3,338
Duloxetine Hcl34$2,827

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvokana$235$19,48516 claims
MerckJanuvia$13$16,19611 claims
AbbVieSynthroid$225$1,68719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,138 nurse practitioner providers in New Jersey.

Other nurse practitioner in Sewell

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →